Biosergen AB (8N1) Stock Statistics & Valuation Metrics

Biosergen AB has a market cap or net worth of €13.58M. The enterprise value is €47.54M.

Biosergen AB has 234,823,210 shares outstanding. The number of shares has decreased by -2.65% in one year.

Biosergen AB’s return on equity (ROE) is -0.38 and return on invested capital (ROIC) is -37.83%.

The current PE Ratio of Biosergen AB is -6.62. Biosergen AB’s PEG ratio is -0.16.

In the last 12 months, Biosergen AB had revenue of 0.00 and earned -18.79M in profits. Earnings per share was -0.08.

In the last 12 months, operating cash flow was -15.59M and capital expenditures 0.00, giving a free cash flow of -15.59M billion.

Biosergen AB pays an annual dividend of ―, resulting in a dividend yield of ―

Biosergen AB upcoming earnings date is Aug 28, 2025, TBA Not Confirmed.

Biosergen AB as a current ratio of 14.25, with Debt / Equity ratio of 0.00%

In the past 12 months, Biosergen AB has paid 0.00 in taxes.

Biosergen AB EV to EBITDA ratio is -3.97, with an EV/FCF ratio of -4.44.

Biosergen AB has €50.61M in cash and marketable securities with kr0.00 in debt, giving a net cash position of -€50.61M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Biosergen AB is ―, which is 11.43% higher than the current price. The consensus rating is ―